Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Regression Models and Life-Tables

1992 • 27,454 citations

Regression Models and Life-Tables

1972 • 27,145 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Revisions in the International System for Staging Lung Cancer

1997 • 4,582 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1984 • 2,762 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 • 2,102 citations

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

2004 • 1,733 citations

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

2004 • 1,723 citations

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

2002 • 910 citations

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

2004 • 749 citations

Druginduced pulmonary disease. Part 1 : Cytotoxic drugs

1986 • 544 citations

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

2001 • 534 citations

United States Food and Drug Administration Drug Approval Summary

2004 • 493 citations

Severe acute interstitial pneumonia and gefitinib

2003 • 445 citations

Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431 Human Carcinoma Cells

1984 • 400 citations

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

2003 • 271 citations

Epidermal growth factor receptor tyrosine kinase

1994 • 258 citations

Interstitial lung disease associated with drug therapy

2004 • 161 citations

Expression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in rats.

1994 • 144 citations

Elevated Transforming Growth Factor- α Levels in Bronchoalveolar Lavage Fluid of Patients with Acute Respiratory Distress Syndrome

1998 • 126 citations

Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.

2003 • 115 citations

Drug-induced pulmonary disease

1987 • 112 citations

Interstitial Lung Disease in Lung Cancer

2005 • 62 citations

Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer

2003 • 51 citations

Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-α

1999 • 33 citations

Dose-Related Protection from Nickel-Induced Lung Injury in Transgenic Mice Expressing Human Transforming Growth Factor- α

2002 • 31 citations

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer

2004 • 24 citations